Mangoceuticals (MGRX) Equity Average (2023 - 2025)
Mangoceuticals (MGRX) has disclosed Equity Average for 3 consecutive years, with $15.5 million as the latest value for Q4 2025.
- Quarterly Equity Average rose 11.36% to $15.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15.5 million through Dec 2025, up 11.36% year-over-year, with the annual reading at $14.6 million for FY2025, 98.0% up from the prior year.
- Equity Average hit $15.5 million in Q4 2025 for Mangoceuticals, down from $17.5 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $19.7 million in Q2 2025 to a low of -$91857.0 in Q1 2024.
- Historically, Equity Average has averaged $10.0 million across 3 years, with a median of $13.8 million in 2024.
- Biggest YoY gain for Equity Average was 18714.14% in 2025; the steepest drop was 11.36% in 2025.
- Year by year, Equity Average stood at $1.1 million in 2023, then surged by 1204.27% to $13.9 million in 2024, then grew by 11.36% to $15.5 million in 2025.
- Business Quant data shows Equity Average for MGRX at $15.5 million in Q4 2025, $17.5 million in Q3 2025, and $19.7 million in Q2 2025.